# Efficacy and Safety of QD202 in Participants With Acute Ischemic Stroke Undergoing Thrombolysis Excluding Endovascular Thrombectomy

Study · id `cardio:ct-nct07581210` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07581210](<https://clinicaltrials.gov/study/NCT07581210>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07581210

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 120 participants.

## Technical summary

Registry record NCT07581210. Randomized; triple masking; primary purpose treatment. Start 2025-10-14 (actual); primary completion 2026-08 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 120 participants (planned count; ClinicalTrials.gov record NCT07581210, source copy `cardio:ctgov-nct07581210-2026-05-12`, retrieved 2026-10-26)
- Started: 2025-10-14 (actual) (ClinicalTrials.gov record NCT07581210, source copy `cardio:ctgov-nct07581210-2026-05-12`, retrieved 2026-10-26)
- Primary completion: 2026-08 (anticipated) (ClinicalTrials.gov record NCT07581210, source copy `cardio:ctgov-nct07581210-2026-05-12`, retrieved 2026-10-26)
- Completion: 2026-12 (anticipated) (ClinicalTrials.gov record NCT07581210, source copy `cardio:ctgov-nct07581210-2026-05-12`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT07581210, source copy `cardio:ctgov-nct07581210-2026-05-12`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07581210-2026-05-12`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of QD202 in Participants With Acute Ischemic Stroke Undergoing Thrombolysis Excluding Endovascular Thrombectomy
- Condition: Acute Ischemic Stroke
- Intervention (Drug): QD202
- Intervention (Drug): Placebo
- Lead sponsor: Shanghai QuietD Biotechnology Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Stroke (`core:stroke`)

## Provenance

Content hash: 2ff50646c15129ecc537a8d6d545eb03cd6629efe9f74201039e34d5f057dd2c
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
